Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biologics

PUBLISHER: Visiongain | PRODUCT CODE: 1742441

Cover Image

PUBLISHER: Visiongain | PRODUCT CODE: 1742441

Viral Vectors & Plasmid DNA Manufacturing Market Report 2025-2035

PUBLISHED:
PAGES: 483 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User) - 1 Year License
USD 6003
PDF (Team License - Up to 6 Users) - 1 Year License
USD 7107
PDF (Site License)
USD 8349
PDF (Enterprise License - Includes Free Datasets)
USD 10550.10

Add to Cart

Description

Table of Contents

List of Tables

The global Viral Vectors & Plasmid DNA Manufacturing market is projected to grow at a CAGR of 15.9% by 2035.

The Viral Vectors and Plasmid DNA Manufacturing Market Report 2025-2035 (Including Impact of U.S. Trade Tariffs): This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Rising Demand for Viral Vector Manufacturing for Gene Therapy R&D and Production is Driving Market Growth

Viral vectors are revolutionising the treatment of rare diseases by enabling highly targeted gene therapy approaches. This cutting-edge technology allows for the delivery of corrected genes directly into a patient,Aos cells, addressing the root cause of genetic disorders rather than just managing symptoms. As gene therapy continues to gain traction, the demand for viral vectors and plasmid DNA has surged, driving rapid growth in the manufacturing sector.

To keep pace, pharmaceutical companies are making substantial investments in production infrastructure. For example, on April 22, 2025, Roche announced plans to invest US$50 billion in U.S.-based manufacturing and R&D over the next five years, which includes building a next-generation gene therapy manufacturing facility in Pennsylvania. Likewise on February 6, 2024, AstraZeneca revealed a US$300 million investment to develop a new facility in Rockville, Maryland, dedicated to commercialising cell therapy platforms, with a focus on T-cell therapies. These large-scale initiatives highlight the industry's strong commitment to expanding manufacturing capabilities to support the growing pipeline of gene therapy products.

Stringent Government Regulations Are Hindering Market Growth

Tight regulatory oversight continues to pose a significant barrier to the growth of the viral vector and plasmid DNA manufacturing market, especially as gene therapy gains momentum and demand for these delivery systems rises. Agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have put in place strict standards to ensure the safety, efficacy, and quality of gene therapies that rely on viral vectors. While these rules are essential to protect patients, they also bring added layers of complexity, cost, and potential delays for manufacturers.

One of the most demanding aspects is compliance with Good Manufacturing Practice (GMP) guidelines, which govern every part of the viral vector production process. Meeting GMP standards requires extensive validation, precise documentation, and robust quality control from start to finish from sourcing raw materials to the final product release. For small biotech firms or newcomers to gene therapy manufacturing, achieving GMP compliance can be both financially and logistically overwhelming. In fact, GMP requirements can push manufacturing costs up by 30-50%, making it harder to advance products through development and into the market. A notable example is Bluebird Bio, which experienced delays in launching its gene therapies due to regulatory hurdles linked to quality control standards.

Moreover, getting regulatory approval for viral vector-based therapies is a lengthy and complicated process. Health authorities demand comprehensive clinical evidence and long-term safety data, which often leads to extended review timelines. This requirement significantly slows down the development and commercialization process, as companies must invest considerable time and resources before moving forward with clinical trials or product launches.

What would be the Impact of US Trade Tariffs on the Global Viral Vectors and Plasmid DNA Manufacturing Market ?

The imposition of U.S. trade tariffs on imported raw materials, bioprocessing equipment, and critical components has increased production costs for domestic manufacturers of viral vectors and plasmid DNA. Many U.S.-based biotech firms rely heavily on global supply chains, particularly for sourcing single-use technologies, specialised enzymes, and cell culture media. When tariffs are applied to these imports, manufacturers either absorb the added costs, reducing profitability, or pass them on to customers, which can make gene therapy development more expensive overall. This is especially challenging for emerging biotech companies and contract development and manufacturing organisations (CDMOs) that operate on tighter margins.

Globally, these tariffs have created dribble effects across the supply chain. International suppliers who traditionally served the U.S. market may seek alternative buyers in Asia or Europe to avoid tariff-related uncertainties. Simultaneously, companies are increasingly diversifying their manufacturing footprints to de-risk operations. This trend has encouraged investment in new manufacturing hubs in regions like Eastern Europe and Southeast Asia, reducing dependency on U.S.-based facilities. As a result, the market is becoming more decentralised, which may benefit global access to gene therapy technologies in the long run but could weaken the U.S.,Aos dominance in this high-growth sector.

Furthermore, the uncertainty introduced by shifting trade policies has pushed many biomanufacturers to reconsider long-term procurement and localisation strategies. Some U.S. firms are now investing in domestic alternatives to reduce reliance on foreign components, while others are forming joint ventures or entering strategic alliances to secure stable access to critical materials outside tariff zones. While these adjustments may promote greater supply chain resilience, they often involve substantial upfront investment and longer lead times, which can temporarily disrupt innovation cycles. Overall, trade tariffs are reshaping the global viral vector and plasmid DNA landscape by influencing where and how companies choose to produce these essential components.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the viral vectors and plasmid DNA manufacturing market evolving?
  • What is driving and restraining the viral vectors and plasmid DNA manufacturing market?
  • How will each viral vectors and plasmid DNA manufacturing submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
  • How will the market shares for each viral vectors and plasmid DNA manufacturing submarket develop from 2025 to 2035?
  • What will be the main driver for the overall market from 2025 to 2035?
  • Will leading viral vectors and plasmid DNA manufacturing markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the viral vectors and plasmid DNA manufacturing projects for these leading companies?
  • How will the industry evolve during the period between 2025 and 2035? What are the implications of viral vectors and plasmid DNA manufacturing projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the viral vectors and plasmid DNA manufacturing market?
  • Where is the viral vectors and plasmid DNA manufacturing market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the viral vectors and plasmid DNA manufacturing market today, and over the next 10 years:

  • Our 483-page report provides 213 tables and 278 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them - NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.
  • Forecasts to 2035 and other analysis reveal commercial prospects
  • In addition to revenue forecasting to 2035, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analysis, with business outlooks and developments.
  • Discover qualitative analysis (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising viral vectors and plasmid DNA manufacturing prices and recent developments.

Segments Covered in the Report

  • Type
  • Viral Vectors
  • Retroviruses
  • Adenoviruses
  • Adeno-associated viruses (AAVs)
  • Lentiviruses
  • Others
  • Plasmid DNA
  • Product and Service
  • Products
  • Services
  • Workflow
  • Upstream Manufacturing
  • Vector Amplification/Editing and Expansion
  • Vector Recovery/Harvesting
  • Downstream Manufacturing
  • Purification
  • Fill Finish
  • Application
  • Cell and Gene Therapy
  • Vaccine Development
  • Research
  • Others
  • Indication
  • Cancer
  • Generic Disorders
  • Infectious Diseases
  • Others
  • End-users
  • Pharmaceutical and Biopharmaceutical Companies
  • Academics and Research Institutes
  • Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 25 leading national markets:

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of Latin America
  • MEA
  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles and for some of the leading companies in the Viral Vectors and Plasmid DNA Manufacturing Market, 2025 to 2035, with a focus on this segment of these companies'operations.

  • Leading companies profiled in the report
  • 3PBIOVIAN
  • Addgene
  • Advanced BioScience Laboratories Inc.
  • Aldevron
  • Altogen Biosystems
  • Amicus Therapeutics
  • ATUM
  • Batavia Biosciences B.V.
  • BioNTech SE
  • bluebird bio Inc.
  • Boehringer Ingelheim
  • Catalent Inc.
  • Charles River Laboratories
  • Creative Biogene
  • Cytiva
  • FUJIFILM Diosynth Biotechnologies
  • Genezen
  • Lonza Group Ltd.
  • Merck KGaA
  • Novartis
  • Recipharm AB
  • RegenxBio Inc
  • SK pharmteco
  • Thermo Fisher Scientific Inc.
  • uniQure N.V.
  • VGXI, Inc.
  • Virovek
  • VIVEbiotech
  • Waisman Biomanufacturing
  • Wuxi AppTec

Overall world revenue for Viral Vectors and Plasmid DNA Manufacturing Market, 2025 to 2035 in terms of value the market will surpass US$6.0 billion in 2025, our work calculates. We predict strong revenue growth through to 2035. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

  • How will the Viral Vectors and Plasmid DNA Manufacturing Market, 2025 to 2035 report help you?
  • In summary, our 480+ page report provides you with the following knowledge:
  • Revenue forecasts to 2035 for Viral Vectors and Plasmid DNA Manufacturing Market, 2025 to 2035, with forecasts for type, product and services, workflow, application, indication, and end-users, each forecast at a global and regional level - discover the industry,Aos prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2035 for five regional and 21 key national markets - See forecasts for the Viral Vectors and Plasmid DNA Manufacturing Market, 2025 to 2035 in North America, Europe, Asia Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 30 of the major companies involved in the Viral Vectors and Plasmid DNA Manufacturing Market, 2025 to 2035.
  • Find quantitative and qualitative analysis with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
  • Information found nowhere else
  • With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analysis, and decisions. Visiongain,Aos study is for everybody needing commercial analysis for the Viral Vectors and Plasmid DNA Manufacturing Market, 2025 to 2035, market-leading companies. You will find data, trends and predictions.
Show more
Product Code: PHA1352

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Viral Vectors and Plasmid DNA Manufacturing Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
  • 3.3 Impact Analysis
    • 3.3.1 Market Driving Factors
      • 3.3.1.1 Rising Demand for Viral Vectors Manufacturing for the R&D and Production of Gene Therapy Solutions
      • 3.3.1.2 Advancements in Biotechnology, Facilitating Precision Medicine And Innovative Therapies
      • 3.3.1.3 Increasing Investments in Viral Vector Technologies by Biopharmaceutical Companies and CROs
      • 3.3.1.4 Rising Outsourcing of Viral Vector Manufacturing
    • 3.3.2 Market Restraining Factors
      • 3.3.2.1 High Costs Associated with Viral Vector and Plasmid DNA Manufacturing
      • 3.3.2.2 Stringent Government Regulation is Hindering the Market Growth
      • 3.3.2.3 High Cost Associated with Gene & Cell Therapy
      • 3.3.2.4 Challenges Associated with Scaling Up Production While Maintaining Quality and Consistency
      • 3.3.2.5 Intense Competition Among Vendors
    • 3.3.3 Market Opportunities
      • 3.3.3.1 Investments in New Production Facilities and Partnerships To Meet The Growing Demand For Viral Vectors
      • 3.3.3.2 Expanding Applications in the Fields of Regenerative Medicine, Gene Therapy, and Vaccine Development
      • 3.3.3.3 Innovations in Manufacturing Processes
  • 3.4 U.S. Tariffs: What,Aos the Impact on Global Viral Vectors and Plasmid DNA Manufacturing Market?
    • 3.4.1 Overview
    • 3.4.2 V-Shaped Recovery Scenario
      • 3.4.2.1 Why V-Shaped Recovery?
      • 3.4.2.2 Impact from Tariffs
      • 3.4.2.3 Market Dynamics and Demand Recovery
      • 3.4.2.4 Policy and Funding Support
      • 3.4.2.5 Timeframe for Recovery
    • 3.4.3 U-Shaped Recovery Scenario
      • 3.4.3.1 Why U-Shaped Recovery?
      • 3.4.3.2 Impact from Tariffs
      • 3.4.3.3 Market Dynamics and Demand Recovery
      • 3.4.3.4 Policy and Funding Support
      • 3.4.3.5 Timeframe for Recovery
    • 3.4.4 L Shaped Recovery Scenario
      • 3.4.4.1 Why L-Shaped Recovery?
      • 3.4.4.2 Impact from Tariffs
      • 3.4.4.3 Market Dynamics and Demand Recovery
      • 3.4.4.4 Policy and Funding Support
      • 3.4.4.5 Timeframe for Recovery
    • 3.4.5 What Strategic Considerations Should Clients Factor into Their Near-term (2025-2030) and Long-term (2025-2035) Planning?
    • 3.4.6 Impact of U.S. and China Trade War on Viral Vectors and Plasmid DNA Manufacturing Market
    • 3.4.7 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
  • 3.5 Regulatory Framework
  • 3.6 Emerging Markets and Megatrends
  • 3.7 Porter,Aos Five Forces Analysis
    • 3.7.1 Bargaining Power of Suppliers
    • 3.7.2 Bargaining Power of Buyers
    • 3.7.3 Competitive Rivalry
    • 3.7.4 Threat of Substitutes
    • 3.7.5 Threat of New Entrants
  • 3.8 PEST Analysis

4 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Type

  • 4.1 Key Findings
  • 4.2 Type Segment: Market Attractiveness Index
  • 4.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Type
  • 4.4 Viral Vectors
    • 4.4.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 4.4.2 Market Share by Region, 2025 & 2035 (%)
    • 4.4.3 Viral Vectors Manufacturing Market Size Estimation and Forecast by Type
    • 4.4.4 Adeno-Associated Viruses (AAVs)
      • 4.4.4.1 Market Size by Region, 2025-2035 (US$ Billion)
      • 4.4.4.2 Market Share by Region, 2025 & 2035 (%)
    • 4.4.5 Lentiviruses
      • 4.4.5.1 Market Size by Region, 2025-2035 (US$ Billion)
      • 4.4.5.2 Market Share by Region, 2025 & 2035 (%)
    • 4.4.6 Adenoviruses
      • 4.4.6.1 Market Size by Region, 2025-2035 (US$ Billion)
      • 4.4.6.2 Market Share by Region, 2025 & 2035 (%)
    • 4.4.7 Retroviruses
      • 4.4.7.1 Market Size by Region, 2025-2035 (US$ Billion)
      • 4.4.7.2 Market Share by Region, 2025 & 2035 (%)
    • 4.4.8 Others
      • 4.4.8.1 Market Size by Region, 2025-2035 (US$ Billion)
      • 4.4.8.2 Market Share by Region, 2025 & 2035 (%)
  • 4.5 Plasmid DNA
    • 4.5.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 4.5.2 Market Share by Region, 2025 & 2035 (%)

5 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Product and Service

  • 5.1 Key Findings
  • 5.2 Product and Service Segment: Market Attractiveness Index
  • 5.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Product and Service
  • 5.4 Product
    • 5.4.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 5.4.2 Market Share by Region, 2025 & 2035 (%)
  • 5.5 Services
    • 5.5.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 5.5.2 Market Share by Region, 2025 & 2035 (%)

6 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Workflow

  • 6.1 Key Findings
  • 6.2 Workflow Segment: Market Attractiveness Index
  • 6.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
  • 6.4 Downstream Manufacturing
    • 6.4.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 6.4.2 Market Share by Region, 2025 & 2035 (%)
    • 6.4.3 Downstream Manufacturing Market Size Estimation and Forecast by Type
    • 6.4.4 Purification
      • 6.4.4.1 Market Size by Region, 2025-2035 (US$ Billion)
      • 6.4.4.2 Market Share by Region, 2025 & 2035 (%)
    • 6.4.5 Fill Finish
      • 6.4.5.1 Market Size by Region, 2025-2035 (US$ Billion)
      • 6.4.5.2 Market Share by Region, 2025 & 2035 (%)
  • 6.5 Upstream Manufacturing
    • 6.5.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 6.5.2 Market Share by Region, 2025 & 2035 (%)
    • 6.5.3 Upstream Manufacturing Market Size Estimation and Forecast by Type
    • 6.5.4 Vector Amplification and Expansion
      • 6.5.4.1 Market Size by Region, 2025-2035 (US$ Billion)
      • 6.5.4.2 Market Share by Region, 2025 & 2035 (%)
    • 6.5.5 Vector Recovery/Harvesting
      • 6.5.5.1 Market Size by Region, 2025-2035 (US$ Billion)
      • 6.5.5.2 Market Share by Region, 2025 & 2035 (%)

7 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Application

  • 7.1 Key Findings
  • 7.2 Application Segment: Market Attractiveness Index
  • 7.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
  • 7.4 Vaccine Development
    • 7.4.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 7.4.2 Market Share by Region, 2025 & 2035 (%)
  • 7.5 Cell Therapy
    • 7.5.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 7.5.2 Market Share by Region, 2025 & 2035 (%)
  • 7.6 Gene Therapy
    • 7.6.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 7.6.2 Market Share by Region, 2025 & 2035 (%)
  • 7.7 Antisense & RNAi Therapy
    • 7.7.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 7.7.2 Market Share by Region, 2025 & 2035 (%)
  • 7.8 Others
    • 7.8.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 7.8.2 Market Share by Region, 2025 & 2035 (%)

8 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Indication

  • 8.1 Key Findings
  • 8.2 Indication Segment: Market Attractiveness Index
  • 8.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Indication
  • 8.4 Cancer
    • 8.4.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 8.4.2 Market Share by Region, 2025 & 2035 (%)
  • 8.5 Infectious Diseases
    • 8.5.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 8.5.2 Market Share by Region, 2025 & 2035 (%)
  • 8.6 Genetic Disorders
    • 8.6.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 8.6.2 Market Share by Region, 2025 & 2035 (%)
  • 8.7 Others
    • 8.7.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 8.7.2 Market Share by Region, 2025 & 2035 (%)

9 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by End-user

  • 9.1 Key Findings
  • 9.2 End-user Segment: Market Attractiveness Index
  • 9.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-user
  • 9.4 Biotechnology and Biopharmaceutical Companies
    • 9.4.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 9.4.2 Market Share by Region, 2025 & 2035 (%)
  • 9.5 CDMOs
    • 9.5.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 9.5.2 Market Share by Region, 2025 & 2035 (%)
  • 9.6 Academics and Research Institutes
    • 9.6.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 9.6.2 Market Share by Region, 2025 & 2035 (%)
  • 9.7 Others
    • 9.7.1 Market Size by Region, 2025-2035 (US$ Billion)
    • 9.7.2 Market Share by Region, 2025 & 2035 (%)

10 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Region

  • 10.1 Key Findings
  • 10.2 Regional Market Size Estimation and Forecast

11 North America Viral Vectors and Plasmid DNA Manufacturing Market Analysis

  • 11.1 Key Findings
  • 11.2 North America Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
  • 11.3 North America Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Billion)
  • 11.4 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
  • 11.5 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Type
    • 11.5.1 North America Viral Vectors Manufacturing Market Size Estimation and Forecast by Type
  • 11.6 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Product and Service
  • 11.7 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
    • 11.7.1 North America Downstream Manufacturing Market Size Estimation and Forecast by Type
    • 11.7.2 North America Upstream Manufacturing Market Size Estimation and Forecast by Type
  • 11.8 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
  • 11.9 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Indication
  • 11.10 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-users
  • 11.11 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 11.12 Canada Viral Vectors and Plasmid DNA Manufacturing Market Analysis

12 Europe Viral Vectors and Plasmid DNA Manufacturing Market Analysis

  • 12.1 Key Findings
  • 12.2 Europe Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
  • 12.3 Europe Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Billion)
  • 12.4 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
  • 12.5 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Type
    • 12.5.1 Europe Viral Vectors Manufacturing Market Size Estimation and Forecast by Type
  • 12.6 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Product and Service
  • 12.7 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
    • 12.7.1 Europe Downstream Manufacturing Market Size Estimation and Forecast by Type
    • 12.7.2 Europe Upstream Manufacturing Market Size Estimation and Forecast by Type
  • 12.8 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
  • 12.9 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Indication
  • 12.10 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-users
  • 12.11 Germany Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 12.12 UK Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 12.13 France Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 12.14 Italy Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 12.15 Spain Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 12.16 Russia Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 12.17 Netherlands Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 12.18 Denmark Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 12.19 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Analysis

13 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Analysis

  • 13.1 Key Findings
  • 13.2 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
  • 13.3 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Billion)
  • 13.4 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
  • 13.5 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Type
    • 13.5.1 Asia Pacific Viral Vectors Manufacturing Market Size Estimation and Forecast by Type
  • 13.6 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Product and Service
  • 13.7 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
    • 13.7.1 Asia Pacific Downstream Manufacturing Market Size Estimation and Forecast by Type
    • 13.7.2 Asia Pacific Upstream Manufacturing Market Size Estimation and Forecast by Type
  • 13.8 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
  • 13.9 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Indication
  • 13.10 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-users
  • 13.11 Japan Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 13.12 China Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 13.13 India Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 13.14 Australia Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 13.15 South Korea Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 13.16 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Analysis

14 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Analysis

  • 14.1 Key Findings
  • 14.2 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
  • 14.3 Latin America Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Billion)
  • 14.4 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
  • 14.5 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Type
    • 14.5.1 Latin America Viral Vectors Manufacturing Market Size Estimation and Forecast by Type
  • 14.6 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Product and Service
  • 14.7 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
    • 14.7.1 Latin America Downstream Manufacturing Market Size Estimation and Forecast by Type
    • 14.7.2 Latin America Upstream Manufacturing Market Size Estimation and Forecast by Type
  • 14.8 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
  • 14.9 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Indication
  • 14.10 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-users
  • 14.11 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 14.12 Mexico Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 14.13 Argentina Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 14.14 Colombia Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 14.15 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Analysis

15 MEA Viral Vectors and Plasmid DNA Manufacturing Market Analysis

  • 15.1 Key Findings
  • 15.2 MEA Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
  • 15.3 MEA Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Billion)
  • 15.4 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
  • 15.5 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Type
    • 15.5.1 MEA Viral Vectors Manufacturing Market Size Estimation and Forecast by Type
  • 15.6 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Product and Service
  • 15.7 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
    • 15.7.1 MEA Downstream Manufacturing Market Size Estimation and Forecast by Type
    • 15.7.2 MEA Upstream Manufacturing Market Size Estimation and Forecast by Type
  • 15.8 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
  • 15.9 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Indication
  • 15.10 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-users
  • 15.11 GCC Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 15.12 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Analysis
  • 15.13 Rest of MEA Viral Vectors and Plasmid DNA Manufacturing Market Analysis

16 Company Profiles

  • 16.1 Competitive Landscape, 2024
  • 16.2 Strategic Outlook
  • 16.3 Lonza Group Ltd.
    • 16.3.1 Company Snapshot
    • 16.3.2 Company Overview
    • 16.3.3 Financial Analysis
      • 16.3.3.1 Net Revenue, 2020-2024
      • 16.3.3.2 R&D, 2020-2024
      • 16.3.3.3 Regional Market Shares, 2024
    • 16.3.4 Product Benchmarking
    • 16.3.5 Strategic Outlook
    • 16.3.6 SWOT Analysis
  • 16.4 Merck KGaA
    • 16.4.1 Company Snapshot
    • 16.4.2 Company Overview
    • 16.4.3 Financial Analysis
      • 16.4.3.1 Net Revenue, 2020-2024
      • 16.4.3.2 R&D, 2020-2024
      • 16.4.3.3 Regional Market Shares, 2024
    • 16.4.4 Product Benchmarking
    • 16.4.5 Strategic Outlook
    • 16.4.6 SWOT Analysis
  • 16.5 uniQure N.V.
    • 16.5.1 Company Snapshot
    • 16.5.2 Company Overview
    • 16.5.3 Financial Analysis
      • 16.5.3.1 Net Revenue, 2020-2024
      • 16.5.3.2 R&D, 2020-2024
      • 16.5.3.3 Business Market Shares, 2024
    • 16.5.4 Product Benchmarking
    • 16.5.5 Strategic Outlook
  • 16.6 Catalent Inc.
    • 16.6.1 Company Snapshot
    • 16.6.2 Company Overview
    • 16.6.3 Financial Analysis
      • 16.6.3.1 Net Revenue, 2020-2024
      • 16.6.3.2 R&D, 2020-2024
      • 16.6.3.3 Business Market Shares, 2024
    • 16.6.4 Product Benchmarking
    • 16.6.5 Strategic Outlook
    • 16.6.6 SWOT Analysis
  • 16.7 Thermo Fisher Scientific Inc.
    • 16.7.1 Company Snapshot
    • 16.7.2 Company Overview
    • 16.7.3 Financial Analysis
      • 16.7.3.1 Net Revenue, 2020-2024
      • 16.7.3.2 R&D, 2020-2024
      • 16.7.3.3 Regional Market Shares, 2024
      • 16.7.3.4 Business Market Shares, 2024
    • 16.7.4 Product Benchmarking
    • 16.7.5 Strategic Outlook
    • 16.7.6 SWOT Analysis
  • 16.8 Charles River Laboratories
    • 16.8.1 Company Snapshot
    • 16.8.2 Company Overview
    • 16.8.3 Financial Analysis
      • 16.8.3.1 Net Revenue, 2020-2024
      • 16.8.3.2 Regional Market Shares, 2024
    • 16.8.4 Product Benchmarking
    • 16.8.5 Strategic Outlook
    • 16.8.6 SWOT Analysis
  • 16.9 FUJIFILM Diosynth Biotechnologies
    • 16.9.1 Company Snapshot
    • 16.9.2 Company Overview
    • 16.9.3 Product Benchmarking
    • 16.9.4 Strategic Outlook
  • 16.10 bluebird bio Inc.
    • 16.10.1 Company Snapshot
    • 16.10.2 Company Overview
    • 16.10.3 Financial Analysis
      • 16.10.3.1 Net Revenue, 2020-2024
      • 16.10.3.2 R&D, 2020-2024
    • 16.10.4 Product Benchmarking
    • 16.10.5 Strategic Outlook
  • 16.11 Aldevron
    • 16.11.1 Company Snapshot
    • 16.11.2 Company Overview
    • 16.11.3 Product Benchmarking
    • 16.11.4 Strategic Outlook
  • 16.12 Addgene
    • 16.12.1 Company Snapshot
    • 16.12.2 Company Overview
    • 16.12.3 Product Benchmarking
    • 16.12.4 Strategic Outlook
  • 16.13 Creative Biogene
    • 16.13.1 Company Snapshot
    • 16.13.2 Company Overview
    • 16.13.3 Product Benchmarking
  • 16.14 VIVEbiotech
    • 16.14.1 Company Snapshot
    • 16.14.2 Company Overview
    • 16.14.3 Financial Analysis
      • 16.14.3.1 Net Revenue, 2020-2024
    • 16.14.4 Product Benchmarking
    • 16.14.5 Strategic Outlook
  • 16.15 Recipharm AB
    • 16.15.1 Company Snapshot
    • 16.15.2 Company Overview
    • 16.15.3 Financial Analysis
      • 16.15.3.1 Net Revenue, 2020-2024
    • 16.15.4 Product Benchmarking
    • 16.15.5 Strategic Outlook
  • 16.16 Waisman Biomanufacturing
    • 16.16.1 Company Snapshot
    • 16.16.2 Company Overview
    • 16.16.3 Product Benchmarking
  • 16.17 VGXI, Inc.
    • 16.17.1 Company Snapshot
    • 16.17.2 Company Overview
    • 16.17.3 Product Benchmarking
    • 16.17.4 Strategic Outlook
  • 16.18 Batavia Biosciences B.V.
    • 16.18.1 Company Snapshot
    • 16.18.2 Company Overview
    • 16.18.3 Product Benchmarking
    • 16.18.4 Strategic Outlook
  • 16.19 WuXi AppTec
    • 16.19.1 Company Snapshot
    • 16.19.2 Company Overview
    • 16.19.1 Financial Analysis
      • 16.19.1.1 Net Revenue, 2020-2024
      • 16.19.1.2 Regional Market Shares, 2024
      • 16.19.1.3 Business Segment Market Shares, 2024
    • 16.19.2 Product Benchmarking
    • 16.19.3 Strategic Outlook
  • 16.20 ATUM
    • 16.20.1 Company Snapshot
    • 16.20.2 Company Overview
    • 16.20.3 Product Benchmarking
    • 16.20.4 Strategic Outlook
  • 16.21 Altogen Biosystems
    • 16.21.1 Company Snapshot
    • 16.21.2 Company Overview
    • 16.21.3 Product Benchmarking
    • 16.21.4 Strategic Outlook
  • 16.22 GENEZEN
    • 16.22.1 Company Snapshot
    • 16.22.2 Company Overview
    • 16.22.3 Product Benchmarking
    • 16.22.4 Strategic Outlook
  • 16.23 SK pharmteco
    • 16.23.1 Company Snapshot
    • 16.23.2 Company Overview
    • 16.23.3 Financial Analysis
      • 16.23.3.1 Net Revenue, 2020-2024
    • 16.23.4 Product Benchmarking
    • 16.23.5 Strategic Outlook
  • 16.24 Cytiva
    • 16.24.1 Company Snapshot
    • 16.24.2 Company Overview
    • 16.24.3 Product Benchmarking
    • 16.24.4 Strategic Outlook
  • 16.25 Virovek
    • 16.25.1 Company Snapshot
    • 16.25.2 Company Overview
    • 16.25.3 Product Benchmarking
    • 16.25.4 Strategic Outlook
  • 16.26 Advanced BioScience Laboratories Inc. (ABL)
    • 16.26.1 Company Snapshot
    • 16.26.2 Company Overview
    • 16.26.3 Product Benchmarking
    • 16.26.4 Strategic Outlook
  • 16.27 3PBIOVIAN
    • 16.27.1 Company Snapshot
    • 16.27.2 Company Overview
    • 16.27.3 Product Benchmarking
    • 16.27.4 Strategic Outlook
  • 16.28 BioNTech SE
    • 16.28.1 Company Snapshot
    • 16.28.2 Company Overview
    • 16.28.3 Financial Analysis
      • 16.28.3.1 Net Revenue, 2020-2024
      • 16.28.3.2 R&D, 2020-2024
    • 16.28.4 Product Benchmarking
    • 16.28.5 Strategic Outlook
  • 16.29 RegenxBio Inc.
    • 16.29.1 Company Snapshot
    • 16.29.2 Company Overview
    • 16.29.3 Financial Analysis
      • 16.29.3.1 Net Revenue, 2020-2024
      • 16.29.3.2 R&D, 2020-2024
    • 16.29.4 Product Benchmarking
  • 16.30 Novartis
    • 16.30.1 Company Snapshot
    • 16.30.2 Company Overview
    • 16.30.3 Financial Analysis
      • 16.30.3.1 Net Revenue, 2020-2024
      • 16.30.3.2 R&D, 2020-2024
      • 16.30.3.3 Regional Market Shares, 2024
      • 16.30.3.4 Business Segment Market Shares, 2024
    • 16.30.4 Product Benchmarking
    • 16.30.5 Strategic Outlook
  • 16.31 Boehringer Ingelheim International GmbH
    • 16.31.1 Company Snapshot
    • 16.31.2 Company Overview
    • 16.31.3 Financial Analysis
      • 16.31.3.1 Net Revenue, 2020-2024
      • 16.31.3.2 R&D, 2020-2024
      • 16.31.3.3 Regional Market Shares, 2024
      • 16.31.3.4 Business Segment Market Shares, 2024
    • 16.31.4 Product Benchmarking
    • 16.31.5 Strategic Outlook
  • 16.32 Amicus Therapeutics
    • 16.32.1 Company Snapshot
    • 16.32.2 Company Overview
    • 16.32.3 Financial Analysis
      • 16.32.3.1 Net Revenue, 2020-2024
      • 16.32.3.2 R&D, 2020-2024
    • 16.32.4 Product Benchmarking
    • 16.32.5 Strategic Outlook

17 Conclusion and Recommendations

  • 17.1 Concluding Remarks from Visiongain
  • 17.2 Recommendations for Market Players
Show more
Product Code: PHA1352

List of Tables

  • Table 1 Viral Vectors and Plasmid DNA Manufacturing Market Snapshot, 2025 & 2035 (US$ Billion, CAGR %)
  • Table 2 Approved Cellular and Gene Therapy Products, 2025
  • Table 3 Viral Vectors and Plasmid DNA Manufacturing Market: International Trade Tariff Impact Recovery Scenarios Snapshot
  • Table 4 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region 2025-2035 (US$ Billion, AGR%, CAGR%), Tariff Impact: V- Shaped Recovery Scenario
  • Table 5 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region 2025-2035 (US$ Billion, AGR%, CAGR%), Tariff Impact: U- Shaped Recovery Scenario
  • Table 6 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region 2025-2035 (US$ Billion, AGR%, CAGR%), Tariff Impact: L- Shaped Recovery Scenario
  • Table 7 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 8 Viral Vectors Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 9 Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 10 Adeno-Associated Viruses (AAVs) Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 11 Lentiviruses Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 12 Adenoviruses Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 13 Retroviruses Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 14 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 15 Plasmid DNA Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 16 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 17 Product Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 18 Services Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 19 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 20 Downstream Manufacturing Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 21 Downstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 22 Purification Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 23 Fill Finish Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 24 Upstream Manufacturing Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 25 Upstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 26 Vector Amplification and Expansion Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 27 Vector Recovery/Harvesting Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 28 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 29 Vaccine Development Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 30 Cell Therapy Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 31 Gene Therapy Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 32 Antisense & RNAi Therapy Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 33 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 34 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 35 Cancer Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 36 Infectious Diseases Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 37 Genetic Disorders Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 38 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 39 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-user, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 40 Biotechnology and Biopharmaceutical Companies Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 41 CDMOs Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 42 Academics and Research Institutes Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 43 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 44 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 45 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 46 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 47 North America Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 48 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 49 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 50 North America Downstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 51 North America Upstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 52 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 53 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 54 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-user, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 55 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 56 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 57 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 58 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 59 Europe Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 60 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 61 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 62 Europe Downstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 63 Europe Upstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 64 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 65 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 66 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-user, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 67 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 68 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 69 France Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 70 Italy Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 71 Spain Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 72 Russia Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 73 Netherlands Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 74 Denmark Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 75 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 76 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 77 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 78 Asia Pacific Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 79 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 80 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 81 Asia Pacific Downstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 82 Asia Pacific Upstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 83 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 84 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 85 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-user, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 86 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 87 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 88 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 89 Australia Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 90 South Korea Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 91 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 92 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 93 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 94 Latin America Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 95 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 96 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 97 Latin America Downstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 98 Latin America Upstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 99 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 100 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 101 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-user, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 102 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 103 Mexico Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 104 Argentina Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 105 Colombia Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 106 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 107 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 108 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 109 MEA Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 110 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 111 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 112 MEA Downstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 113 MEA Upstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 114 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 115 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 116 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-user, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 117 GCC Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 118 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 119 Rest of MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR%, CAGR%)
  • Table 120 Strategic Outlook
  • Table 121 Lonza Group Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 122 Lonza Group Ltd.: Product Benchmarking
  • Table 123 Lonza: Strategic Outlook
  • Table 124 Lonza: SWOT Analysis
  • Table 125 Merck KGaA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 126 Merck KGaA: Product Benchmarking
  • Table 127 Merck KGaA: Strategic Outlook
  • Table 128 Merck KGaA: SWOT Analysis
  • Table 129 uniQure N.V.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 130 uniQure N.V. : Product Benchmarking
  • Table 131 uniQure N.V.: Strategic Outlook
  • Table 132 Catalent Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 133 Catalent Inc.: Product Benchmarking
  • Table 134 Catalent Inc.: Strategic Outlook
  • Table 135 Catalent Inc.: SWOT Analysis
  • Table 136 Thermo Fisher Scientific Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 137 Thermo Fisher Scientific Inc.: Product Benchmarking
  • Table 138 Thermo Fisher Scientific Inc.: Strategic Outlook
  • Table 139 Thermo Fisher Scientific Inc.: SWOT Analysis
  • Table 140 Charles River Laboratories: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 141 Charles River Laboratories: Product Benchmarking
  • Table 142 Charles River Laboratories: Strategic Outlook
  • Table 143 Charles River Laboratories: SWOT Analysis
  • Table 144 FUJIFILM Diosynth Biotechnologies: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 145 FUJIFILM Diosynth Biotechnologies: Product Benchmarking
  • Table 146 FUJIFILM Diosynth Biotechnologies: Strategic Outlook
  • Table 147 bluebird bio Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 148 bluebird bio Inc.: Product Benchmarking
  • Table 149 bluebird bio Inc.: Strategic Outlook
  • Table 150 Aldevron: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 151 Aldevron: Product Benchmarking
  • Table 152 Aldevron: Strategic Outlook
  • Table 153 Addgene: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 154 Addgene: Product Benchmarking
  • Table 155 Addgene: Strategic Outlook
  • Table 156 Creative Biogene: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 157 Creative Biogene: Product Benchmarking
  • Table 158 VIVEbiotech: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 159 VIVEbiotech: Product Benchmarking
  • Table 160 VIVEbiotech: Strategic Outlook
  • Table 161 Recipharm AB: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 162 Recifarm AB: Product Benchmarking
  • Table 163 Recipharm AB: Strategic Outlook
  • Table 164 Waisman Biomanufacturing: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 165 Waisman Biomanufacturing: Product Benchmarking
  • Table 166 VGXI, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 167 VGXI, Inc. : Product Benchmarking
  • Table 168 VGXI Inc.: Strategic Outlook
  • Table 169 Batavia Biosciences B.V.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 170 Batavia Biosciences B.V. : Product Benchmarking
  • Table 171 Batavia Biosciences B.V.: Strategic Outlook
  • Table 172 WuXi AppTec: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 173 Wuxi AppTec: Product Benchmarking
  • Table 174 WuXi AppTec: Strategic Outlook
  • Table 175 ATUM: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 176 ATUM: Product Benchmarking
  • Table 177 ATUM: Strategic Outlook
  • Table 178 Altogen Biosystems: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 179 Altogen Biosystems: Product Benchmarking
  • Table 180 Altogen Biosystems: Strategic Outlook
  • Table 181 Genezen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 182 Genezen: Product Benchmarking
  • Table 183 GENEZEN: Strategic Outlook
  • Table 184 SK pharmteco: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 185 SK pharmteco: Product Benchmarking
  • Table 186 SK pharmteco: Strategic Outlook
  • Table 187 Cytiva: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 188 Cytiva: Product Benchmarking
  • Table 189 Cytiva: Strategic Outlook
  • Table 190 Virovek: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 191 Virovek : Product Benchmarking
  • Table 192 Virovek: Strategic Outlook
  • Table 193 Advanced BioScience Laboratories Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 194 Advanced BioScience Laboratories Inc.: Product Benchmarking
  • Table 195 Advanced BioScience Laboratories Inc.: Strategic Outlook
  • Table 196 3PBIOVIAN: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 197 3PBIOVIAN: Product Benchmarking
  • Table 198 3PBIOVIAN: Strategic Outlook
  • Table 199 BioNTech SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 200 BioNTech SE: Product Benchmarking
  • Table 201 BioNTech SE: Strategic Outlook
  • Table 202 RegenxBio Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 203 RegenxBio Inc.: Product Benchmarking
  • Table 204 Novartis: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 205 Novartis: Product Benchmarking
  • Table 206 Novartis: Strategic Outlook
  • Table 207 Boehringer Ingelheim International GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 208 Boehringer Ingelheim International GmbH: Product Benchmarking
  • Table 209 Boehringer Ingelheim International GmbH: Strategic Outlook
  • Table 210 Amicus Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 211 Amicus Therapeutics : Product Benchmarking
  • Table 212 Amicus Therapeutics: Strategic Outlook

List of Figures

  • Figure 1 Viral Vectors and Plasmid DNA Manufacturing Market Segmentation
  • Figure 2 Viral Vectors and Plasmid DNA Manufacturing Market by Type: Market Attractiveness Index
  • Figure 3 Viral Vectors and Plasmid DNA Manufacturing Market by Product and Service: Market Attractiveness Index
  • Figure 4 Viral Vectors and Plasmid DNA Manufacturing Market by Workflow: Market Attractiveness Index
  • Figure 5 Viral Vectors and Plasmid DNA Manufacturing Market by Application: Market Attractiveness Index
  • Figure 6 Viral Vectors and Plasmid DNA Manufacturing Market by Indication: Market Attractiveness Index
  • Figure 7 Viral Vectors and Plasmid DNA Manufacturing Market by End-user: Market Attractiveness Index
  • Figure 8 Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index by Region
  • Figure 9 Viral Vectors and Plasmid DNA Manufacturing Market: Market Dynamics
  • Figure 10 Viral Vectors and Plasmid DNA Manufacturing Market: Impact Analysis
  • Figure 11 Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2025-2035 (US$ Million, AGR %), Tariff Impact: V-Shaped Recovery Scenario
  • Figure 12 Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2025-2035 (US$ Million, AGR %), Tariff Impact: U-Shaped Recovery Scenario
  • Figure 13 Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2025-2035 (US$ Million, AGR %), Tariff Impact: L-Shaped Recovery Scenario
  • Figure 14 Short Term & Long Term Planning
  • Figure 15 Impact of U.S. and China Trade War
  • Figure 16 Most Impacted Countries
  • Figure 17 Viral Vectors and Plasmid DNA Manufacturing Market: Porter's Five Forces Analysis
  • Figure 18 Viral Vectors and Plasmid DNA Manufacturing Market: PEST Analysis
  • Figure 19 Viral Vectors and Plasmid DNA Manufacturing Market by Type: Market Attractiveness Index
  • Figure 20 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 21 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Type, 2025, 2030, 2035 (%)
  • Figure 22 Viral Vectors Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 23 Viral Vectors Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 24 Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 25 Viral Vectors Manufacturing Market Share Forecast by Type, 2025, 2030, 2035 (%)
  • Figure 26 Adeno-Associated Viruses (AAVs) Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 27 Adeno-Associated Viruses (AAVs) Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 28 Lentiviruses Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 29 Lentiviruses Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 30 Adenoviruses Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 31 Adenoviruses Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 32 Retroviruses Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 33 Retroviruses Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 34 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 35 Others Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 36 Plasmid DNA Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 37 Plasmid DNA Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 38 Viral Vectors and Plasmid DNA Manufacturing Market by Product and Service: Market Attractiveness Index
  • Figure 39 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR %)
  • Figure 40 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Product and Service, 2025, 2030, 2035 (%)
  • Figure 41 Product Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 42 Product Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 43 Services Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 44 Services Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 45 Viral Vectors and Plasmid DNA Manufacturing Market by Workflow: Market Attractiveness Index
  • Figure 46 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR %)
  • Figure 47 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2025, 2030, 2035 (%)
  • Figure 48 Downstream Manufacturing Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 49 Downstream Manufacturing Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 50 Downstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 51 Downstream Manufacturing Market Share Forecast by Type, 2025, 2030, 2035 (%)
  • Figure 52 Purification Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 53 Purification Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 54 Fill Finish Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 55 Fill Finish Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 56 Upstream Manufacturing Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 57 Upstream Manufacturing Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 58 Upstream Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 59 Upstream Manufacturing Market Share Forecast by Type, 2025, 2030, 2035 (%)
  • Figure 60 Vector Amplification and Expansion Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 61 Vector Amplification and Expansion Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 62 Vector Recovery/Harvesting Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 63 Vector Recovery/Harvesting Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 64 Viral Vectors and Plasmid DNA Manufacturing Market by Application: Market Attractiveness Index
  • Figure 65 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR %)
  • Figure 66 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2025, 2030, 2035 (%)
  • Figure 67 Vaccine Development Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 68 Vaccine Development Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 69 Cell Therapy Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 70 Cell Therapy Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 71 Gene Therapy Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 72 Gene Therapy Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 73 Antisense & RNAi Therapy Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 74 Antisense & RNAi Therapy Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 75 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 76 Others Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 77 Viral Vectors and Plasmid DNA Manufacturing Market by Indication: Market Attractiveness Index
  • Figure 78 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR %)
  • Figure 79 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Indication, 2025, 2030, 2035 (%)
  • Figure 80 Cancer Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 81 Cancer Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 82 Infectious Diseases Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 83 Infectious Diseases Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 84 Genetic Disorders Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 85 Genetic Disorders Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 86 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 87 Others Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 88 Viral Vectors and Plasmid DNA Manufacturing Market by End-user: Market Attractiveness Index
  • Figure 89 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-user, 2025-2035 (US$ Billion, AGR %)
  • Figure 90 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-user, 2025, 2030, 2035 (%)
  • Figure 91 Biotechnology and Biopharmaceutical Companies Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 92 Biotechnology and Biopharmaceutical Companies Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 93 CDMOs Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 94 CDMOs Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 95 Academics and Research Institutes Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 96 Academics and Research Institutes Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 97 Others Segment Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 98 Others Segment Market Share Forecast by Region, 2025 & 2035 (%)
  • Figure 99 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region 2025 and 2035 (Revenue, CAGR%)
  • Figure 100 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Region 2025, 2030, 2035 (%)
  • Figure 101 Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2025-2035 (US$ Billion, AGR %)
  • Figure 102 North America Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
  • Figure 103 North America Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2025, 2030 & 2035 (US$ Billion)
  • Figure 104 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
  • Figure 105 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country, 2025 & 2035 (%)
  • Figure 106 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 107 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Type, 2025 & 2035 (%)
  • Figure 108 North America Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 109 North America Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
  • Figure 110 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR %)
  • Figure 111 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Product and Service, 2025 & 2035 (%)
  • Figure 112 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR %)
  • Figure 113 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2025 & 2035 (%)
  • Figure 114 North America Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 115 North America Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
  • Figure 116 North America Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 117 North America Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
  • Figure 118 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR %)
  • Figure 119 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2025 & 2035 (%)
  • Figure 120 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR %)
  • Figure 121 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Indication, 2025 & 2035 (%)
  • Figure 122 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-users, 2025-2035 (US$ Billion, AGR %)
  • Figure 123 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-users, 2025 & 2035 (%)
  • Figure 124 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 125 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 126 Europe Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
  • Figure 127 Europe Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2025, 2030 & 2035 (US$ Billion)
  • Figure 128 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
  • Figure 129 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country, 2025 & 2035 (%)
  • Figure 130 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 131 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Type, 2025 & 2035 (%)
  • Figure 132 Europe Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 133 Europe Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
  • Figure 134 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR %)
  • Figure 135 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Product and Service, 2025 & 2035 (%)
  • Figure 136 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR %)
  • Figure 137 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2025 & 2035 (%)
  • Figure 138 Europe Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 139 Europe Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
  • Figure 140 Europe Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 141 Europe Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
  • Figure 142 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR %)
  • Figure 143 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2025 & 2035 (%)
  • Figure 144 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR %)
  • Figure 145 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Indication, 2025 & 2035 (%)
  • Figure 146 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-users, 2025-2035 (US$ Billion, AGR %)
  • Figure 147 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-users, 2025 & 2035 (%)
  • Figure 148 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 149 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 150 France Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 151 Italy Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 152 Spain Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 153 Russia Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 154 Netherlands Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 155 Denmark Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 156 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 157 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
  • Figure 158 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2025, 2030 & 2035 (US$ Billion)
  • Figure 159 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
  • Figure 160 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country, 2025 & 2035 (%)
  • Figure 161 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 162 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Type, 2025 & 2035 (%)
  • Figure 163 Asia Pacific Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 164 Asia Pacific Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
  • Figure 165 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR %)
  • Figure 166 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Product and Service, 2025 & 2035 (%)
  • Figure 167 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR %)
  • Figure 168 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2025 & 2035 (%)
  • Figure 169 Asia Pacific Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 170 Asia Pacific Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
  • Figure 171 Asia Pacific Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 172 Asia Pacific Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
  • Figure 173 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR %)
  • Figure 174 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2025 & 2035 (%)
  • Figure 175 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR %)
  • Figure 176 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Indication, 2025 & 2035 (%)
  • Figure 177 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-users, 2025-2035 (US$ Billion, AGR %)
  • Figure 178 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-users, 2025 & 2035 (%)
  • Figure 179 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 180 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 181 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 182 Australia Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 183 South Korea Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 184 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 185 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
  • Figure 186 Latin America Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2025, 2030 & 2035 (US$ Billion)
  • Figure 187 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
  • Figure 188 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country, 2025 & 2035 (%)
  • Figure 189 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 190 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Type, 2025 & 2035 (%)
  • Figure 191 Latin America Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 192 Latin America Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
  • Figure 193 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR %)
  • Figure 194 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Product and Service, 2025 & 2035 (%)
  • Figure 195 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR %)
  • Figure 196 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2025 & 2035 (%)
  • Figure 197 Latin America Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 198 Latin America Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
  • Figure 199 Latin America Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 200 Latin America Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
  • Figure 201 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR %)
  • Figure 202 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2025 & 2035 (%)
  • Figure 203 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR %)
  • Figure 204 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Indication, 2025 & 2035 (%)
  • Figure 205 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-users, 2025-2035 (US$ Billion, AGR %)
  • Figure 206 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-users, 2025 & 2035 (%)
  • Figure 207 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 208 Mexico Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 209 Argentina Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 210 Colombia Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 211 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 212 MEA Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
  • Figure 213 MEA Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2025, 2030 & 2035 (US$ Billion)
  • Figure 214 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2025-2035 (US$ Billion, AGR %)
  • Figure 215 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country, 2025 & 2035 (%)
  • Figure 216 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 217 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Type, 2025 & 2035 (%)
  • Figure 218 MEA Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 219 MEA Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
  • Figure 220 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Product and Service, 2025-2035 (US$ Billion, AGR %)
  • Figure 221 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Product and Service, 2025 & 2035 (%)
  • Figure 222 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2025-2035 (US$ Billion, AGR %)
  • Figure 223 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2025 & 2035 (%)
  • Figure 224 MEA Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 225 MEA Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
  • Figure 226 MEA Viral Vectors Manufacturing Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • Figure 227 MEA Viral Vectors Manufacturing Market Forecast by Type, 2025 & 2035 (%)
  • Figure 228 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2025-2035 (US$ Billion, AGR %)
  • Figure 229 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2025 & 2035 (%)
  • Figure 230 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Indication, 2025-2035 (US$ Billion, AGR %)
  • Figure 231 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Indication, 2025 & 2035 (%)
  • Figure 232 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-users, 2025-2035 (US$ Billion, AGR %)
  • Figure 233 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-users, 2025 & 2035 (%)
  • Figure 234 GCC Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 235 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 236 Rest of MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2025-2035 (US$ Billion, AGR %)
  • Figure 237 Viral Vectors and Plasmid DNA Manufacturing Market: Company Share, 2024
  • Figure 238 Lonza Group Ltd.: Net Revenue, 2020-2024 (US$ Million, AGR%)
  • Figure 239 Lonza Group Ltd.: R&D, 2020-2024 (US$ Million, AGR%)
  • Figure 240 Lonza Group: Regional Market Shares, 2024
  • Figure 241 Merck KGaA: Net Revenue, 2020-2024 (US$ Million, AGR%)
  • Figure 242 Merck KGaA: R&D, 2020-2024 (US$ Million, AGR%)
  • Figure 243 Merck KGaA: Regional Market Shares, 2024
  • Figure 244 uniQure N.V.: Net Revenue, 2020-2024 (US$ Million, AGR%)
  • Figure 245 uniQure N.V.: R&D, 2020-2024 (US$ Million, AGR%)
  • Figure 246 uniQure N.V.: Net Revenue: Business Market Shares, 2024
  • Figure 247 Catalent Inc.: Net Revenue, 2020-2024 (US$ Million, AGR%)
  • Figure 248 Catalent Inc.: R&D, 2020-2024 (US$ Million, AGR%)
  • Figure 249 Catalent Inc.: Business Market Shares, 2024
  • Figure 250 Thermo Fisher Scientific Inc.: Net Revenue, 2020-2024 (US$ Million, AGR%)
  • Figure 251 Thermo Fisher Scientific Inc.: R&D, 2020-2024 (US$ Million, AGR%)
  • Figure 252 Thermo Fisher Scientific Inc.: Regional Market Shares, 2024
  • Figure 253 Thermo Fisher Scientific Inc.: Business Market Shares, 2024
  • Figure 254 Charles River Laboratories: Net Revenue, 2020-2024 (US$ Million, AGR%)
  • Figure 255 Charles River Laboratories International Inc: Regional Market Shares, 2024
  • Figure 256 bluebird bio Inc.: Net Revenue, 2020-2024 (US$ Million, AGR%)
  • Figure 257 bluebird bio Inc.: R&D, 2020-2024 (US$ Million, AGR%)
  • Figure 258 VIVEbiotech: Net Revenue, 2020-2024 (US$ Million, AGR%)
  • Figure 259 Recifarm AB: Net Revenue, 2020-2024 (US$ Million, AGR%)
  • Figure 260 Wuxi AppTec: Net Revenue, 2020-2024 (US$ Million, AGR%)
  • Figure 261 Wuxi AppTec: Regional Market Shares, 2024
  • Figure 262 Wuxi AppTec: Business Segment Market Shares, 2024
  • Figure 263 SK pharmteco: Net Revenue, 2020-2024 (US$ Million, AGR%)
  • Figure 264 BioNTech SE: Net Revenue, 2020-2024 (US$ Million, AGR%)
  • Figure 265 BioNTech SE: R&D, 2020-2024 (US$ Million, AGR%)
  • Figure 266 RegenxBio Inc.: Net Revenue, 2020-2024 (US$ Million, AGR%)
  • Figure 267 RegenxBio Inc.: R&D, 2020-2024 (US$ Million, AGR%)
  • Figure 268 Novartis: Net Revenue, 2020-2024 (US$ Million, AGR%)
  • Figure 269 Novartis: R&D, 2020-2024 (US$ Million, AGR%)
  • Figure 270 Novartis: Regional Market Shares, 2024
  • Figure 271 Novartis: Business Segment Market Shares, 2024
  • Figure 272 Boehringer Ingelheim International GmbH: Net Revenue, 2020-2024 (US$ Million, AGR%)
  • Figure 273 Boehringer Ingelheim International GmbH: R&D, 2020-2024 (US$ Million, AGR%)
  • Figure 274 Boehringer Ingelheim International GmbH: Regional Market Shares, 2024
  • Figure 275 Boehringer Ingelheim International GmbH: Business Segment Market Shares, 2024
  • Figure 276 Amicus Therapeutics: Net Revenue, 2020-2024 (US$ Million, AGR%)
  • Figure 277 Amicus Therapeutics: R&D, 2020-2024 (US$ Million, AGR%)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!